JX-594
Phase 2Biologic
JX-594 is one of 115 biologic programs targeting Colorectal Carcinoma. It is currently in Phase 2.
3
Indications
4
Total Trials
0
Active Trials
114
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Cotellic
RochePhase 3
Nexavar
BayerPhase 3
ABP 234
AmgenPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
GSK 257049
GSKPhase 3
Recombinant Human GM-CSF
EEastern Cooperative Oncology Group
Phase 3
Isolated Perfusion
NNational Cancer Institute (NCI)
Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
Intron a
Merck & Co.Preclinical
Opdualag
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Colorectal Carcinoma2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JX-594. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- JJennerex Biotherapeutics